NVCR- NAS (USA) Also traded in: Germany, Mexico
NovoCure Ltd

Not Rated

Top Ranked Predictable Companies

$79.78

4.19(5.54%) Volume: 292,535 2:29PM EDT

Avg Vol (1m): 548,654

Warning! GuruFocus has detected 1 Severe Warning Sign with NAS:NVCR. Click here to check it out.

Market Cap : 8.31 B	Enterprise Value : 7.55 B	PE Ratio : At Loss	PB Ratio : 18.19

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Fundamental
- 5-Year EBITDA Growth Rate
- Altman Z-Score
- Beneish M-Score
- Book Value per Share
- Cash per Share
- Dividends per Share
- E10
- Earnings per Share (Diluted)
- EBIT per Share
- EBITDA per Share
- Enterprise Value
- EPS without NRI
- FFO per Share
- Financial Strength
- Float Percentage Of Total Shares Outstanding
- Free Cash Flow per Share
- GF Score
- GF Value Rank
- Growth Rank
- Insider Ownership
- Institutional Ownership
- Market Cap
- Momentum Rank
- Net Cash per Share
- Net Current Asset Value
- Net-Net Working Capital
- Operating Cash Flow per Share
- Owner Earnings per Share (TTM)
- Piotroski F-Score
- Predictability Rank
- Probability of Financial Distress (%)
- Profitability Rank
- Quality Rank
- Revenue per Share
- Scaled Net Operating Assets
- Short Interest
- Short Percentage of Float
- Tangible Book per Share
- Total Debt per Share
- Valuation Rank
- YoY EBITDA Growth
- YoY EPS Growth
- YoY Rev. per Sh. Growth
Valuation Ratio
- Asset Turnover
- Buyback Yield %
- Capex-to-Operating-Cash-Flow
- Capex-to-Operating-Income
- Capex-to-Revenue
- Cash Conversion Cycle
- Cash Ratio
- Cash-to-Debt
- COGS-to-Revenue
- Current Ratio
- Days Inventory
- Days Payable
- Days Sales Outstanding
- Debt-to-Asset
- Debt-to-EBITDA
- Debt-to-Equity
- Debt-to-Revenue
- Earnings Yield %
- Earnings Yield (Joel Greenblatt) %
- Effective Interest Rate on Debt %
- Equity-to-Asset
- EV-to-EBIT
- EV-to-EBITDA
- EV-to-FCF
- EV-to-Revenue
- Forward PE Ratio
- Forward Rate of Return (Yacktman) %
- Goodwill-to-Asset
- Gross-Profit-to-Asset %
- Interest Coverage
- Inventory Turnover
- Inventory-to-Revenue
- Liabilities-to-Assets
- LT-Debt-to-Total-Asset
- PB Ratio
- PE Ratio
- PE Ratio
- PE Ratio without NRI
- PEG Ratio
- Price-to-Free-Cash-Flow
- Price-to-Funds-From-Operations
- Price-to-Operating-Cash-Flow
- Price-to-Owner-Earnings
- Price-to-Tangible-Book
- PS Ratio
- Quick Ratio
- Return-on-Tangible-Asset
- Return-on-Tangible-Equity
- ROA %
- ROC %
- ROC (Joel Greenblatt) %
- ROCE %
- ROE %
- ROE % Adjusted to Book Value
- ROIC %
- Shares Buyback Ratio %
- Shiller PE Ratio
- Short Ratio
- Sloan Ratio %
- Total Payout Ratio
- Total Payout Yield %
- WACC %
Profitability
- EBITDA Margin %
- FCF Margin %
- Gross Margin %
- Net Interest Margin (Bank Only) %
- Net Margin %
- Operating Margin %
Price
- Beta
- Earnings Power Value (EPV)
- GF Value
- Graham Number
- Intrinsic Value: DCF (Earnings Based)
- Intrinsic Value: DCF (FCF Based)
- Intrinsic Value: Projected FCF
- Margin of Safety % (DCF Earnings Based)
- Median PS Value
- Peter Lynch Fair Value
- Volatility
Dividends
- 3-Year Dividend Growth Rate
- 5-Year Dividend Growth Rate
- 5-Year Yield-on-Cost %
- Dividend Payout Ratio
- Dividend Yield %
- Dividend-Payout-to-FFO
- Forward Dividend Yield %
Income Statement
- Cost of Goods Sold
- Credit Losses Provision
- Depreciation, Depletion and Amortization
- EBIT
- EBITDA
- EPS (Basic)
- EPS (Diluted)
- Fees and Other Income
- Gross Profit
- Interest Expense
- Interest Expense (Positive)
- Interest Income
- Net Income
- Net Income (Continuing Operations)
- Net Income (Discontinued Operations)
- Net Interest Income
- Net Interest Income (for Banks)
- Net Investment Income
- Net Policyholder Benefits/Claims
- Non Interest Income
- Non Operating Income
- Operating Income
- Other Expense
- Other Income (Expense)
- Other Income (Minority Interest)
- Other Noninterest Expense
- Other Operating Expense
- Policy Acquisition Expense
- Pre-Tax Income
- Preferred Dividends
- Research & Development
- Revenue
- Selling, General, & Admin. Expense
- Shares Outstanding (Basic Average)
- Shares Outstanding (Diluted Average)
- SpecialCharges
- Tax Expense
- Tax Provision
- Tax Rate %
- Total Expenses
- Total Noninterest Expense
- Total Operating Expense
- Total Premiums Earned
Balance Sheet
- Accounts Payable
- Accounts Payable & Accrued Expense
- Accounts Payable & Accrued Expense for Financial Companies
- Accounts Receivable
- Accumulated Depreciation
- Accumulated other comprehensive income (loss)
- Additional Paid-In Capital
- Allowance For Loans And Lease Losses
- Buildings And Improvements
- Cash And Cash Equivalents
- Cash and cash equivalents
- Cash, Cash Equivalents, Marketable Securities
- Common Stock
- Construction In Progress
- Current Accrued Expense
- Current Deferred Revenue
- Current Deferred Taxes Liabilities
- Deferred Policy Acquisition Costs
- DeferredTaxAndRevenue
- Equity Investments
- Fixed Maturity Investment
- Future Policy Benefits
- Goodwill
- Gross Loan
- Gross Property, Plant and Equipment
- Intangible Assets
- Inventories, Finished Goods
- Inventories, Inventories Adjustments
- Inventories, Other
- Inventories, Raw Materials & Components
- Inventories, Work In Process
- Investments And Advances
- Land And Improvements
- Loans Receivable
- Long-Term Capital Lease Obligation
- Long-Term Debt
- Long-Term Debt & Capital Lease Obligation
- Machinery, Furniture, Equipment
- Marketable Securities
- Minority Interest
- Money Market Investments
- Net Loan
- NonCurrent Deferred Liabilities
- Notes Receivable
- Other Assets for Banks
- Other Assets for Insurance Companies
- Other Current Assets
- Other Current Liabilities
- Other Current Payables
- Other Current Receivables
- Other Gross PPE
- Other Liabilities for Banks
- Other Liabilities for Insurance Companies
- Other Long Term Assets
- Other Long-Term Liabilities
- Other Stockholders Equity
- PensionAndRetirementBenefit
- Policyholder Funds
- Preferred Stock
- Property, Plant and Equipment
- Retained Earnings
- Securities & Investments
- Shares Outstanding (EOP)
- Short-Term Capital Lease Obligation
- Short-Term Debt
- Short-Term Debt & Capital Lease Obligation
- Short-term investments
- Total Assets
- Total Current Assets
- Total Current Liabilities
- Total Deposits
- Total Equity
- Total Inventories
- Total Liabilities
- Total Long-Term Assets
- Total Long-Term Liabilities
- Total Receivables
- Total Stockholders Equity
- Total Tax Payable
- Treasury Stock
- Unearned Income
- Unearned Premiums
- Unpaid Loss & Loss Reserve
Cashflow Statement
- All Taxes Paid
- Asset Impairment Charge
- Beginning Cash Position
- Capital Expenditure
- Cash Flow for Dividends
- Cash Flow from Discontinued Operations
- Cash Flow from Financing
- Cash Flow from Investing
- Cash Flow from Operations
- Cash Flow from Others
- Cash From Discontinued Investing Activities
- Cash from Discontinued Operating Activities
- Cash From Other Investing Activities
- Cash Paid for Insurance Activities
- Cash Payments
- Cash Payments for Deposits by Banks and Customers
- Cash Payments for Loans
- Cash Receipts from Deposits by Banks and Customers
- Cash Receipts from Fees and Commissions
- Cash Receipts from Loans
- Cash Receipts from Operating Activities
- Cash Receipts from Securities Related Activities
- Cash Receipts from Tax Refunds
- Cash Received from Insurance Activities
- Change In Inventory
- Change In Other Working Capital
- Change In Payables And Accrued Expense
- Change In Prepaid Assets
- Change In Receivables
- Change In Working Capital
- Deferred Tax
- Depreciation, Depletion and Amortization
- Dividends Paid
- Dividends Received
- Effect of Exchange Rate Changes
- Ending Cash Position
- FFO
- Free Cash Flow
- Interest and Commission Paid
- Interest Paid
- Interest Received
- Issuance of Debt
- Issuance of Stock
- Net Change in Cash
- Net Income From Continuing Operations
- Net Intangibles Purchase And Sale
- Net Issuance of Debt
- Net Issuance of Preferred Stock
- Other Cash Payments from Operating Activities
- Other Cash Receipts from Operating Activities
- Other Financing
- Payments of Debt
- Payments on Behalf of Employees
- Payments to Suppliers for Goods and Services
- Purchase Of Business
- Purchase Of Investment
- Purchase Of Property, Plant, Equipment
- Receipts from Customers
- Receipts from Government Grants
- Repurchase of Stock
- Sale Of Business
- Sale Of Investment
- Sale Of Property, Plant, Equipment
- Stock Based Compensation
- Taxes Refund Paid
Technical Indicator
- 5-Day RSI
- 9-Day RSI
- 14-Day RSI
- 50-Day SMA
- 6-Month Price Index
- 6-1 Month Momentum %
- 12-1 Month Momentum %

NovoCure Additional Paid-In Capital

: $1,127.8 Mil(As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

NovoCure's quarterly additional paid-in capital increased from Sep. 2021 ($1,073.5 Mil) to Dec. 2021 ($1,099.6 Mil) and increased from Dec. 2021 ($1,099.6 Mil) to Mar. 2022 ($1,127.8 Mil).

NovoCure's annual additional paid-in capital increased from Dec. 2019 ($871.4 Mil) to Dec. 2020 ($1,111.4 Mil) but then declined from Dec. 2020 ($1,111.4 Mil) to Dec. 2021 ($1,099.6 Mil).

NovoCure Additional Paid-In Capital Historical Data

The historical data trend for NovoCure's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Additional Paid-In Capital

697.17

757.31

871.44

1,111.44

1,099.59

NovoCure Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Additional Paid-In Capital																1,005.79	1,044.73	1,073.53	1,099.59	1,127.78

NovoCure Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

NovoCure Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NovoCure's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure Business Description

Industry

Healthcare » Medical Devices & Instruments NAICS : 339112 SIC : 3845

Comparable Companies

NYSE:STVN NZSE:FPH NAS:RGEN NAS:XRAY MIL:AMP NYSE:ATR NAS:MASI NYSE:NVST NAS:AZTA LSE:CTEC

Traded in Other Exchanges

NVCR:Mexico 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

Executives

Weinberg Uri	officer: Chief Science Officer	NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Groenhuysen Wilhelmus Cm	officer: Chief Operating Officer	C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654
Danziger Asaf	director, officer: Chief Executive Officer	5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302
Leung Gabriel	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960
Shah Pritesh	officer: Chief Commercial Officer	C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Leonard Frank X	officer: Chief Development Officer	20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Cordova Ashley	officer: Chief Financial Officer	20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Madden Martin J.	director	C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043
Benaim Ely	officer: Chief Medical Officer	C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Doyle William F	director, officer: Executive Chairman	PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ambrogi Michael J.	officer: Chief Operating Officer	195 COMMERCE WAY PORTSMOUTH NH 03801
Longsworth Todd Christopher	officer: General Counsel	NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Hilleman Jeryl L	director	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mccoy Sherilyn S	director	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Hung David	director	C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018

NovoCure Headlines

From GuruFocus

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile� Therapy in Recurrent Glioblastoma

By Business Wire 05-25-2021

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial

By Business Wire 03-24-2022

Other Sources

$NVCR - NovoCure: High-Income Options Trade, Bullish Vertical Put Spread. Novocure High Income Options Trade Bullish Vertical Put Spread

By Seekingalpha 2021-07-02

$NVCR - NovoCure Limited 2021 Q3 - Results - Earnings Call Presentation. Novocure Limited 2021 Q3 Results Earnings Call Presentation

By Seekingalpha 2021-10-28

$NVCR - NovoCure Limited 2021 Q2 - Results - Earnings Call Presentation. Novocure Limited 2021 Q2 Results Earnings Call Presentation

By Seekingalpha 2021-07-30

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

NovoCure Additional Paid-In Capital

NovoCure Additional Paid-In Capital Historical Data

NovoCure Additional Paid-In Capital Calculation

NovoCure Additional Paid-In Capital Related Terms

NovoCure Business Description

NovoCure Headlines

Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma

Novocure to Report Third Quarter 2021 Financial Results

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile� Therapy in Recurrent Glioblastoma

Novocure to Report First Quarter 2022 Financial Results

Novocure (NVCR) CEO Asaf Danziger Bought $509,537 of Shares

Novocure to Participate in Two Upcoming Investor Conferences

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial

$NVCR - NovoCure: High-Income Options Trade, Bullish Vertical Put Spread. Novocure High Income Options Trade Bullish Vertical Put Spread

Why Novocure Stock Is Jumping Today

Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment

Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates

$NVCR - NovoCure Limited 2021 Q3 - Results - Earnings Call Presentation. Novocure Limited 2021 Q3 Results Earnings Call Presentation

$NVCR - NovoCure Limited 2021 Q2 - Results - Earnings Call Presentation. Novocure Limited 2021 Q2 Results Earnings Call Presentation

$NVCR - NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2021 Results - Earnings Call Transcript.…

This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?

Here's Why Novocure Dipped 19% This Week

$NVCR - NovoCure: Threshold Of Greatness. Novocure Threshold Of Greatness

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

J.P. Morgan Keeps a Hold Rating on NovoCure (NVCR)

Why Novocure Tanked on Thursday

NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates

This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now